We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$498M
AUM Growth
+$258M
Cap. Flow
+$49.1M
Cap. Flow %
9.86%
Top 10 Hldgs %
69.52%
Holding
145
New
57
Increased
20
Reduced
22
Closed
41

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$6.99M
3
MRNA icon
Moderna
MRNA
+$3.94M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$3.78M
5
MTVA
MetaVia Inc
MTVA
+$3.18M

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$2.89M
2
ENLV icon
Enlivex Ltd
ENLV
+$2.31M
3
NOVN
Novan, Inc. Common Stock
NOVN
+$2.11M
4
OTLK icon
Outlook Therapeutics
OTLK
+$1.94M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.32%
2 Industrials 0.26%
3 Technology 0.12%
4 Consumer Discretionary 0.09%
5 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEUM
101
PUT
DELISTED
Pareteum Corporation
TEUM
$12K ﹤0.01%
190
-382
-67% -$211
AMRN
102
CALL
Amarin Corp
AMRN
$293M
– –
-9
Closed -$75K
AMRN
103
Amarin Corp
AMRN
$293M
– –
-7,500
Closed -$600K
BNBX
104
DELISTED
BNB PLUS CORP
BNBX
– –
-2
Closed -$106K
ASTC icon
105
Astrotech Corp
ASTC
$12.9M
– –
-3,322
Closed -$259K
BLIN icon
106
Bridgeline Digital
BLIN
$14.9M
– –
-110,000
Closed -$73K
COCP icon
107
Cocrystal Pharma
COCP
$12.9M
– –
-32,684
Closed -$278K
CTXR icon
108
Citius Pharmaceuticals
CTXR
$13.7M
– –
-54,171
Closed -$813K
EFOI icon
109
Energy Focus
EFOI
$17.7M
– –
-7,637
Closed -$195K
GILD icon
110
CALL
Gilead Sciences
GILD
$167B
– –
-2,166
Closed -$2.76M
GLD icon
111
SPDR Gold Trust
GLD
$131B
– –
-17,934
Closed -$2.89M
GNPX icon
112
PUT
Genprex
GNPX
$4.05M
– –
0
– -$107K
HEPA
113
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-73
Closed -$128K
HSDT icon
114
Solana Company
HSDT
$98.7M
– –
-1
Closed -$246K
INDP icon
115
CALL
Indaptus Therapeutics
INDP
$231M
– –
0
– -$3K
IWM icon
116
iShares Russell 2000 ETF
IWM
$80.4B
– –
-5,900
Closed -$675K
MYO icon
117
Myomo
MYO
$36.9M
– –
-51,588
Closed -$184K
OTLK icon
118
Outlook Therapeutics
OTLK
$169M
– –
-161,617
Closed -$1.94M
PHIO icon
119
Phio Pharmaceuticals
PHIO
$11.7M
– –
-2,363
Closed -$452K
HIND
120
Vyome Holdings
HIND
$14M
– –
0
– -$124K
SINT icon
121
SiNtx Technologies
SINT
$9.92M
– –
-1
Closed -$7K
TENX icon
122
Tenax Therapeutics
TENX
$419M
– –
-21
Closed -$19K
TLPH icon
123
PUT
Talphera
TLPH
$67.5M
– –
-11
Closed -$26K
TOVX icon
124
Theriva Biologics
TOVX
$9.8M
– –
-308
Closed -$25K
XBIO icon
125
Xenetic Biosciences
XBIO
$5.73M
– –
-6,052
Closed -$45K
2 3 4
5
6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sabby Management held 145 positions worth $498M, up 107% from $241M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management deployed $49.1M of net new capital in Q2 2020, opening 57 new positions and adding to 20 existing holdings. Its largest new stake was Biogen: 103,902 shares worth $27.8M.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, up from 7.3% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Enlivex Ltd, an estimated $2.31M trimmed.

  • Sabby Management's largest Q2 2020 buy was Biogen: 103,902 shares worth $27.8M.
  • Sabby Management added most to State Street Health Care Select Sector SPDR ETF in Q2 2020, an estimated $6.99M increase.
  • Sabby Management's biggest Q2 2020 reduction was Enlivex Ltd, cutting an estimated $2.31M.
  • Sabby Management fully exited SPDR Gold Trust in Q2 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 70% of its $498M portfolio in Q2 2020.
  • Sabby Management opened 57 new positions and closed 41 in Q2 2020.
  • Sabby Management's portfolio value rose 107% quarter-over-quarter to $498M.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.